Table 3.

One-Way Sensitivity Analyses of Parameters

	Eradication Therapy		No Eradication Therapy
	Cost ($)	Effectiveness (QALYs)	Cost ($)	Effectiveness (QALYs)
Costs of gastric cancer treatment ($)
7912.80	2174.85	32.64	4760.89	28.12	Dominated
11,869.20	2770.81	32.64	6638.90	28.12	Dominated
Costs of eradication therapy ($)
62.26	2472.47	32.64	5699.90	28.12	Dominated
93.40	2473.18	32.64	5699.90	28.12	Dominated
Costs of H. pylori testing ($)
65.48	2472.46	32.64	5687.02	28.12	Dominated
98.23	2473.18	32.64	5699.90	28.12	Dominated
Costs of gastric cancer screening ($)
23.97	2277.07	32.64	5511.85	28.12	Dominated
35.95	2668.58	32.64	5887.94	28.12	Dominated
Costs of adverse events related to eradication therapy ($)
1.59	2472.79	32.64	5699.90	28.12	Dominated
2.39	2472.86	32.64	5699.90	28.12	Dominated
Success H. pylori eradication rate
56.08%	2513.66	32.58	5699.90	28.12	Dominated
84.12%	2445.42	32.68	5699.90	28.12	Dominated
Probability of developing gastric cancer in H. pylori-positive population
0.26%	2428.77	32.67	4812.13	28.42	Dominated
0.38%	2516.80	32.61	6569.05	27.83	Dominated
Probability of developing gastric cancer in H. pylori eradication population
0.69‰	2226.78	32.73	5699.90	28.12	Dominated
1.04‰	2717.51	32.55	5699.90	28.12	Dominated
Utility of H. pylori infection
0.71	2472.83	32.48	5699.90	22.53	Dominated
1	2472.83	32.74	5699.90	31.57	Dominated
Utility of gastric cancer
0.30	2472.83	32.63	5699.90	28.08	Dominated
0.46	2472.83	32.65	5699.90	28.16	Dominated